Global CDMO ten23 health has announced a further expansion of swissfillon’s manufacturing site in Visp Switzerland, which was acquired last October.
The FDA-inspected site currently offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and market supplies. The company is investing in an expansion of supporting areas in an adjacent building, which will provide an additional 1000 sqm of cleanroom space for visual inspection and cold storage as well as cleanroom space for additional services, such as supporting device assembly operations and labelling and secondary packaging.
Prof Hanns-Christian Mahler, CEO of ten23 health, commented: “Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp. Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients.”
swissfillon, a specialist sterile filling of complex pharmaceuticals, based in Visp, Switzerland was acquired by ten23 health in October 2021. ten23 health’s combination of pharmaceutical development services with clinical and commercial fill & finish services offers clients an end-to-end set of capabilities.
